Examiner. Withdrawal of all rejections and reconsideration of the amended claims is requested. An early allowance is earnestly sought.

Respectfully submitted,

Dated: September 10, 2003

Carmella L. Stephens

Carmella L. Stephens
Patent Office Reg. No. 41,328

BAKER BOTTS L.L.P.
30 Rockefeller Plaza
New York, New York 10112-0228

Attorneys for Applicants
(212) 408-2500

APPENDIX A

IN THE CLAIMS:

Please cancel claims 4-6 and 20-27, without prejudice.

Please insert the following new claims:

---28. (new) A method for activating an imidazoline receptor expressed in a cell comprising contacting said cell with an imidazoleacetic acid-ribotide.

29. (new) A method for activating an imidazoline receptor expressed in a cell comprising contacting said cell with an imidazoleacetic acid-riboside.

30. (New) The method of claim 28 or 29 wherein the methylene group is substituted for the oxygen atom that links the 5' carbon to the phosphate atom in the imidazoleacetic acid-ribotide.

31. (New) The method of claim 28 or 29 wherein the imidazoleacetic acid-ribotide is a 2' or 3' deoxy-IAA-RP.

32. (New) The method of claim 28 or 29 wherein the imidazoleacetic acid-ribotide is a carboxy-methyl or carboxy-ethyl ester of IAA-RP.

33. (New) The method of claim 28 or 29 wherein furan is linked to the number 2 carbon atom of the imadazole ring.

34. (New) The method of claim 28 or 29 wherein furan is linked to the nitrogen closest to the methylene-carboxy side chain of the imidazole ring.

35. (New) The method of claim 28 or 29 wherein the imadazole ring is converted to an imadzoline ring.

36. (New) The method of claim 28 or 29 wherein the activation of the imidazoline receptor results in release of arachidonic acid from said cell.

37. (New) The method of claim 28 or 29 wherein the acitvation of the imidazoline receptor results in release of insulin from said cell.

38. (New) The method of claim 28 or 29 wherein the activation of the imidazoline receptor results in release of catecholamines from said cell.---